Study number 8533-669
Dates
Aug 12 2024-Oct 22 2024
Location
Madison, Wisconsin
Age
18-65
Gender
Males and Females
Compensation
$6,805
Group
G5
Fortrea Madison, WI is recruiting for:
- Healthy Adults, age 18-65
- Body Mass Index between 18-34
- Study involves 1 overnight stay, 10 follow-up visits and 3 phone calls
- Compensation up to $6,805 may be provided for time and participation
- Refer a friend to receive $400 per qualified referral
Mirikizumab (the study drug) is an investigational drug that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with moderately to severely active ulcerative colitis (a bowel disease that causes inflammation in the digestive tract). The study drug is also being developed for the potential treatment of autoimmune diseases (a condition in which the immune system mistakenly attacks the body) and Crohn’s disease (a bowel disease that affects the lining of the digestive tract).
Group 5:
Check-In: Aug 12
Check-Out: Aug 13
Outpatient Visits: Aug 15, 17, 20, 23, 27, Sep 3, 10
Phone Call: Sep 17
Outpatient Visit: Sep 24
Phone Call: Oct 1
Outpatient Visit: Oct 8
Phone Call: Oct 15
Outpatient Visit: Oct 22